
    
      Eligible subjects will be randomized into one of 4 groups; YH12852 0.1 mg, 0.25 mg, 0.5 mg,
      or placebo at the same ratio and will be administered investigational products orally, twice
      daily for 4 weeks and followed up for 2 weeks.
    
  